Login
Sign Up
Login
Sign Up
Features
Pricing
Reg.News
Contact
Login
Sign Up
Search
Providers
Companies
⨯
LIVE
Event in Progress:
Join Here
×
Search
Providers
Companies
⨯
Features
Pricing
Event Hub
Reg.News
Short Interest
Contact
All the news articles and press releases in one place.
UK Reg. News
German Reg. News
Search
Key Announcements
Results / Trading Updates
Get free RNS email alerts for@Model.CurrentFilterValue
Currently filtered for Allergy Therapeutics plc
Clear Filter
Sector
Automobile Industry
Banks
Basic Materials
Building & Construction
Chemicals
Consumer Discretionary Goods
Consumer Discretionary Services
Consumer Staple Goods
Consumer Staple Services
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Finance
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Trusts, ETFs & Funds
Utilities
Market Cap
Below £20m
£20m - £100m
£100m - £300m
£300m - £1bn
£1bn - £10bn
Over £10bn
Filters »
All
UK100
UK250
UK SmallCap
UK Other
Show:
10
25
50
100
«
1
2
3
»
Date / Time
Source
Ticker
Company
Sector
Market Cap
Announcement
08Jul21 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Allergy Therapeutics - AGY to present key scientific findings at EAACI
24Jun21 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Allergy Therapeutics - Trading Update
01Jun21 15:36
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Allergy Therapeutics - Total Voting Rights
06May21 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Completion of treatment phase in G309 study
30Apr21 17:47
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Total Voting Rights
16Apr21 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Appointment of new Group auditors
31Mar21 08:29
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Vesting of Awards under Long Term Incentive Plan
26Mar21 16:39
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Pledge of Shares
11Mar21 12:13
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Pledge of Shares
08Mar21 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
AGY to Present at H.C. Wainwright Conference
03Mar21 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Interim Results for six months ended 31 Dec 2020
13Jan21 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Half Year Trading Update 2021 & Notice of Results
05Jan21 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Initiation of peanut allergy biomarker study
14Dec20 15:58
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Director/PDMR Shareholding
08Dec20 14:42
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Result of Annual General Meeting
20Nov20 13:51
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Grant of Awards under Long Term Incentive Plan
20Nov20 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Director/PDMR Shareholding
10Nov20 07:05
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Annual Report & Accounts and AGM Notification
26Oct20 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Initiation of Grass MATA MPL exploratory study
12Oct20 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Holding(s) in Company
09Oct20 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Director Dealings and Issue of Equity
23Sep20 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Preliminary Results
03Sep20 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
AGY secures VLP technology platform
20Jul20 07:30
EQS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Hardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard
15Jul20 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Trading Update
09Jul20 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Invalidation of Birch MATA MPL phase III results
01Jul20 17:15
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Total Voting Rights
24Jun20 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Trading Update
22Apr20 10:11
RNS-R
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
EAACI review of adjuvants and formulations
01Apr20 13:09
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Grant and Vesting of Awards
09Mar20 07:15
EQS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Hardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth
04Mar20 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Half-year Report
29Jan20 12:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Data for peanut allergy vaccine published in JACI
16Jan20 12:25
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Trading Update & Notice of Results - Replacement
16Jan20 08:00
EQS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Hardman & Co Research: Allergy Therapeutics (AGY): Sales growth well above market average
16Jan20 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Half Year Trading Update & Notice of Results
02Dec19 09:57
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Holdings in Company
29Nov19 10:34
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Holdings in Company
26Nov19 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Update to Grass MATA MPL Ph III clinical programme
25Nov19 12:13
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Result of Annual General Meeting
22Oct19 09:23
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Annual Report and Accounts
26Sep19 07:30
EQS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Hardman & Co Research: Allergy Therapeutics (AGY): Continuing to gain market share
25Sep19 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Preliminary Results
11Jul19 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Trading update
01Jul19 07:21
EQS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Hardman & Co Research: Allergy Therapeutics (AGY): Successful legal outcome removes uncertainty
01Jul19 07:16
EQS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Hardman & Co Research: Oxford BioMedica (OXB): Eying up long-term value
27Jun19 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Successful Litigation Settlement
27Jun19 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Trading Statement
19Jun19 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Board Change
11Jun19 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Holdings in Company
21May19 08:30
EQS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Hardman & Co Research: Titon Holdings Plc (TON): You need hands
21May19 07:15
EQS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Hardman & Co Research: Allergy Therapeutics (AGY): House dust mite vaccine - clinical progress
20May19 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Positive top line phase I results for Acarovac MPL
14May19 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Holdings in Company
13May19 18:14
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Holding(s) in Company
07May19 07:00
RNS-R
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Research Published on Adjuvant Systems
25Apr19 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Regulatory and Trading Update
18Mar19 11:30
EQS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Hardman & Co Research: Allergy Therapeutics (AGY): Take an objective view
18Mar19 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Top Line Phase III results from B301 trial
06Mar19 12:10
EQS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Hardman & Co Research: Allergy Therapeutics (AGY): Strong operating performance driving market share
06Mar19 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Interim Results
17Jan19 09:56
EQS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Hardman & Co Research: Allergy Therapeutics (AGY): Trading update: gaining market share
16Jan19 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Trading Update & Notice of Results
29Nov18 17:59
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Holdings in Company
27Nov18 13:12
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Result of AGM
27Nov18 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
AGM Trading Update
12Nov18 12:00
RNS-R
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Presentation at Jefferies Healthcare Conference
08Nov18 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Directorate Change
07Nov18 18:06
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Holdings in Company
02Nov18 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Grant of Awards under Long Term Incentive Plan
24Oct18 13:25
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Holdings in Company
24Oct18 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Director/PDMR Shareholding
23Oct18 17:29
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Annual Report and Accounts
23Oct18 15:28
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Holdings in Company
27Sep18 07:15
EQS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Hardman & Co Research: Allergy Therapeutics (AGY): 2018 full-year results: solid growth
08Aug18 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Notice of Results
27Jul18 17:26
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Holding(s) in Company
26Jul18 12:02
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Holding(s) in Company
19Jul18 10:19
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Results of Placing and Subscription
19Jul18 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Proposed placing & subscription to raise £10.6m
13Jul18 09:40
EQS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Hardman & Co Research: Allergy Therapeutics (AGY): Steady performance in a tough market
12Jul18 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Trading Update
21May18 12:25
EQS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Hardman & Co Research: Allergy Therapeutics (AGY): Opening the door to registration
21May18 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Positive top-line results from Grass Ph II study
16Mar18 15:38
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Grant of Awards under Long Term Incentive Plan
16Mar18 12:53
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Director/PDMR Shareholding
07Mar18 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Interim Results
28Feb18 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Polyvac® Peanut CMO appointed
12Feb18 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Completion of recruitment in PQ Grass Ph II trial
31Jan18 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Trading Update
10Jan18 15:19
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Holdings in Company
09Jan18 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
PQ Birch Phase III trial completes recruitment
07Dec17 17:08
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Holding(s) in Company
22Nov17 11:36
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Result of AGM
07Nov17 12:59
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Director/PDMR Shareholding
07Nov17 11:54
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Director/PDMR Shareholding
19Oct17 16:14
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Publication of Annual Report and notice of AGM
19Oct17 07:00
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Commencement of dosing in PQ Grass Phase II Trial
12Oct17 17:39
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Holding(s) in Company
12Oct17 14:55
RNS
AGY:LON
Allergy Therapeutics plc
Health
£143.0m
Director/PDMR Shareholding
«
1
2
3
»
Date / Time
Source
Company
% Chg
08Jul21 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - AGY to present key scientific findings at EAACI
24Jun21 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Trading Update
01Jun21 15:36
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Total Voting Rights
06May21 07:00
RNS
Allergy Therapeutics plc
0.00%
Completion of treatment phase in G309 study
30Apr21 17:47
RNS
Allergy Therapeutics plc
0.00%
Total Voting Rights
16Apr21 07:00
RNS
Allergy Therapeutics plc
0.00%
Appointment of new Group auditors
31Mar21 08:29
RNS
Allergy Therapeutics plc
0.00%
Vesting of Awards under Long Term Incentive Plan
26Mar21 16:39
RNS
Allergy Therapeutics plc
0.00%
Pledge of Shares
11Mar21 12:13
RNS
Allergy Therapeutics plc
0.00%
Pledge of Shares
08Mar21 07:00
RNS
Allergy Therapeutics plc
0.00%
AGY to Present at H.C. Wainwright Conference
03Mar21 07:00
RNS
Allergy Therapeutics plc
0.00%
Interim Results for six months ended 31 Dec 2020
13Jan21 07:00
RNS
Allergy Therapeutics plc
0.00%
Half Year Trading Update 2021 & Notice of Results
05Jan21 07:00
RNS
Allergy Therapeutics plc
0.00%
Initiation of peanut allergy biomarker study
14Dec20 15:58
RNS
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
08Dec20 14:42
RNS
Allergy Therapeutics plc
0.00%
Result of Annual General Meeting
20Nov20 13:51
RNS
Allergy Therapeutics plc
0.00%
Grant of Awards under Long Term Incentive Plan
20Nov20 07:00
RNS
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
10Nov20 07:05
RNS
Allergy Therapeutics plc
0.00%
Annual Report & Accounts and AGM Notification
26Oct20 07:00
RNS
Allergy Therapeutics plc
0.00%
Initiation of Grass MATA MPL exploratory study
12Oct20 07:00
RNS
Allergy Therapeutics plc
0.00%
Holding(s) in Company
09Oct20 07:00
RNS
Allergy Therapeutics plc
0.00%
Director Dealings and Issue of Equity
23Sep20 07:00
RNS
Allergy Therapeutics plc
0.00%
Preliminary Results
03Sep20 07:00
RNS
Allergy Therapeutics plc
0.00%
AGY secures VLP technology platform
20Jul20 07:30
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard
15Jul20 07:00
RNS
Allergy Therapeutics plc
0.00%
Trading Update
09Jul20 07:00
RNS
Allergy Therapeutics plc
0.00%
Invalidation of Birch MATA MPL phase III results
01Jul20 17:15
RNS
Allergy Therapeutics plc
0.00%
Total Voting Rights
24Jun20 07:00
RNS
Allergy Therapeutics plc
0.00%
Trading Update
22Apr20 10:11
RNS-R
Allergy Therapeutics plc
0.00%
EAACI review of adjuvants and formulations
01Apr20 13:09
RNS
Allergy Therapeutics plc
0.00%
Grant and Vesting of Awards
09Mar20 07:15
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth
04Mar20 07:00
RNS
Allergy Therapeutics plc
0.00%
Half-year Report
29Jan20 12:00
RNS
Allergy Therapeutics plc
0.00%
Data for peanut allergy vaccine published in JACI
16Jan20 12:25
RNS
Allergy Therapeutics plc
0.00%
Trading Update & Notice of Results - Replacement
16Jan20 08:00
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Sales growth well above market average
16Jan20 07:00
RNS
Allergy Therapeutics plc
0.00%
Half Year Trading Update & Notice of Results
02Dec19 09:57
RNS
Allergy Therapeutics plc
0.00%
Holdings in Company
29Nov19 10:34
RNS
Allergy Therapeutics plc
0.00%
Holdings in Company
26Nov19 07:00
RNS
Allergy Therapeutics plc
0.00%
Update to Grass MATA MPL Ph III clinical programme
25Nov19 12:13
RNS
Allergy Therapeutics plc
0.00%
Result of Annual General Meeting
22Oct19 09:23
RNS
Allergy Therapeutics plc
0.00%
Annual Report and Accounts
26Sep19 07:30
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Continuing to gain market share
25Sep19 07:00
RNS
Allergy Therapeutics plc
0.00%
Preliminary Results
11Jul19 07:00
RNS
Allergy Therapeutics plc
0.00%
Trading update
01Jul19 07:21
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Successful legal outcome removes uncertainty
01Jul19 07:16
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Oxford BioMedica (OXB): Eying up long-term value
27Jun19 07:00
RNS
Allergy Therapeutics plc
0.00%
Successful Litigation Settlement
27Jun19 07:00
RNS
Allergy Therapeutics plc
0.00%
Trading Statement
19Jun19 07:00
RNS
Allergy Therapeutics plc
0.00%
Board Change
11Jun19 07:00
RNS
Allergy Therapeutics plc
0.00%
Holdings in Company
21May19 08:30
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Titon Holdings Plc (TON): You need hands
21May19 07:15
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): House dust mite vaccine - clinical progress
20May19 07:00
RNS
Allergy Therapeutics plc
0.00%
Positive top line phase I results for Acarovac MPL
14May19 07:00
RNS
Allergy Therapeutics plc
0.00%
Holdings in Company
13May19 18:14
RNS
Allergy Therapeutics plc
0.00%
Holding(s) in Company
07May19 07:00
RNS-R
Allergy Therapeutics plc
0.00%
Research Published on Adjuvant Systems
25Apr19 07:00
RNS
Allergy Therapeutics plc
0.00%
Regulatory and Trading Update
18Mar19 11:30
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Take an objective view
18Mar19 07:00
RNS
Allergy Therapeutics plc
0.00%
Top Line Phase III results from B301 trial
06Mar19 12:10
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Strong operating performance driving market share
06Mar19 07:00
RNS
Allergy Therapeutics plc
0.00%
Interim Results
17Jan19 09:56
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Trading update: gaining market share
16Jan19 07:00
RNS
Allergy Therapeutics plc
0.00%
Trading Update & Notice of Results
29Nov18 17:59
RNS
Allergy Therapeutics plc
0.00%
Holdings in Company
27Nov18 13:12
RNS
Allergy Therapeutics plc
0.00%
Result of AGM
27Nov18 07:00
RNS
Allergy Therapeutics plc
0.00%
AGM Trading Update
12Nov18 12:00
RNS-R
Allergy Therapeutics plc
0.00%
Presentation at Jefferies Healthcare Conference
08Nov18 07:00
RNS
Allergy Therapeutics plc
0.00%
Directorate Change
07Nov18 18:06
RNS
Allergy Therapeutics plc
0.00%
Holdings in Company
02Nov18 07:00
RNS
Allergy Therapeutics plc
0.00%
Grant of Awards under Long Term Incentive Plan
24Oct18 13:25
RNS
Allergy Therapeutics plc
0.00%
Holdings in Company
24Oct18 07:00
RNS
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
23Oct18 17:29
RNS
Allergy Therapeutics plc
0.00%
Annual Report and Accounts
23Oct18 15:28
RNS
Allergy Therapeutics plc
0.00%
Holdings in Company
27Sep18 07:15
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): 2018 full-year results: solid growth
08Aug18 07:00
RNS
Allergy Therapeutics plc
0.00%
Notice of Results
27Jul18 17:26
RNS
Allergy Therapeutics plc
0.00%
Holding(s) in Company
26Jul18 12:02
RNS
Allergy Therapeutics plc
0.00%
Holding(s) in Company
19Jul18 10:19
RNS
Allergy Therapeutics plc
0.00%
Results of Placing and Subscription
19Jul18 07:00
RNS
Allergy Therapeutics plc
0.00%
Proposed placing & subscription to raise £10.6m
13Jul18 09:40
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Steady performance in a tough market
12Jul18 07:00
RNS
Allergy Therapeutics plc
0.00%
Trading Update
21May18 12:25
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Opening the door to registration
21May18 07:00
RNS
Allergy Therapeutics plc
0.00%
Positive top-line results from Grass Ph II study
16Mar18 15:38
RNS
Allergy Therapeutics plc
0.00%
Grant of Awards under Long Term Incentive Plan
16Mar18 12:53
RNS
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
07Mar18 07:00
RNS
Allergy Therapeutics plc
0.00%
Interim Results
28Feb18 07:00
RNS
Allergy Therapeutics plc
0.00%
Polyvac® Peanut CMO appointed
12Feb18 07:00
RNS
Allergy Therapeutics plc
0.00%
Completion of recruitment in PQ Grass Ph II trial
31Jan18 07:00
RNS
Allergy Therapeutics plc
0.00%
Trading Update
10Jan18 15:19
RNS
Allergy Therapeutics plc
0.00%
Holdings in Company
09Jan18 07:00
RNS
Allergy Therapeutics plc
0.00%
PQ Birch Phase III trial completes recruitment
07Dec17 17:08
RNS
Allergy Therapeutics plc
0.00%
Holding(s) in Company
22Nov17 11:36
RNS
Allergy Therapeutics plc
0.00%
Result of AGM
07Nov17 12:59
RNS
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
07Nov17 11:54
RNS
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
19Oct17 16:14
RNS
Allergy Therapeutics plc
0.00%
Publication of Annual Report and notice of AGM
19Oct17 07:00
RNS
Allergy Therapeutics plc
0.00%
Commencement of dosing in PQ Grass Phase II Trial
12Oct17 17:39
RNS
Allergy Therapeutics plc
0.00%
Holding(s) in Company
12Oct17 14:55
RNS
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
«
1
2
3
»
Date / Time
Company
% Chg
08Jul21 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - AGY to present key scientific findings at EAACI
24Jun21 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Trading Update
01Jun21 15:36
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Total Voting Rights
06May21 07:00
Allergy Therapeutics plc
0.00%
Completion of treatment phase in G309 study
30Apr21 17:47
Allergy Therapeutics plc
0.00%
Total Voting Rights
16Apr21 07:00
Allergy Therapeutics plc
0.00%
Appointment of new Group auditors
31Mar21 08:29
Allergy Therapeutics plc
0.00%
Vesting of Awards under Long Term Incentive Plan
26Mar21 16:39
Allergy Therapeutics plc
0.00%
Pledge of Shares
11Mar21 12:13
Allergy Therapeutics plc
0.00%
Pledge of Shares
08Mar21 07:00
Allergy Therapeutics plc
0.00%
AGY to Present at H.C. Wainwright Conference
03Mar21 07:00
Allergy Therapeutics plc
0.00%
Interim Results for six months ended 31 Dec 2020
13Jan21 07:00
Allergy Therapeutics plc
0.00%
Half Year Trading Update 2021 & Notice of Results
05Jan21 07:00
Allergy Therapeutics plc
0.00%
Initiation of peanut allergy biomarker study
14Dec20 15:58
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
08Dec20 14:42
Allergy Therapeutics plc
0.00%
Result of Annual General Meeting
20Nov20 13:51
Allergy Therapeutics plc
0.00%
Grant of Awards under Long Term Incentive Plan
20Nov20 07:00
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
10Nov20 07:05
Allergy Therapeutics plc
0.00%
Annual Report & Accounts and AGM Notification
26Oct20 07:00
Allergy Therapeutics plc
0.00%
Initiation of Grass MATA MPL exploratory study
12Oct20 07:00
Allergy Therapeutics plc
0.00%
Holding(s) in Company
09Oct20 07:00
Allergy Therapeutics plc
0.00%
Director Dealings and Issue of Equity
23Sep20 07:00
Allergy Therapeutics plc
0.00%
Preliminary Results
03Sep20 07:00
Allergy Therapeutics plc
0.00%
AGY secures VLP technology platform
20Jul20 07:30
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard
15Jul20 07:00
Allergy Therapeutics plc
0.00%
Trading Update
09Jul20 07:00
Allergy Therapeutics plc
0.00%
Invalidation of Birch MATA MPL phase III results
01Jul20 17:15
Allergy Therapeutics plc
0.00%
Total Voting Rights
24Jun20 07:00
Allergy Therapeutics plc
0.00%
Trading Update
22Apr20 10:11
Allergy Therapeutics plc
0.00%
EAACI review of adjuvants and formulations
01Apr20 13:09
Allergy Therapeutics plc
0.00%
Grant and Vesting of Awards
09Mar20 07:15
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth
04Mar20 07:00
Allergy Therapeutics plc
0.00%
Half-year Report
29Jan20 12:00
Allergy Therapeutics plc
0.00%
Data for peanut allergy vaccine published in JACI
16Jan20 12:25
Allergy Therapeutics plc
0.00%
Trading Update & Notice of Results - Replacement
16Jan20 08:00
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Sales growth well above market average
16Jan20 07:00
Allergy Therapeutics plc
0.00%
Half Year Trading Update & Notice of Results
02Dec19 09:57
Allergy Therapeutics plc
0.00%
Holdings in Company
29Nov19 10:34
Allergy Therapeutics plc
0.00%
Holdings in Company
26Nov19 07:00
Allergy Therapeutics plc
0.00%
Update to Grass MATA MPL Ph III clinical programme
25Nov19 12:13
Allergy Therapeutics plc
0.00%
Result of Annual General Meeting
22Oct19 09:23
Allergy Therapeutics plc
0.00%
Annual Report and Accounts
26Sep19 07:30
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Continuing to gain market share
25Sep19 07:00
Allergy Therapeutics plc
0.00%
Preliminary Results
11Jul19 07:00
Allergy Therapeutics plc
0.00%
Trading update
01Jul19 07:21
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Successful legal outcome removes uncertainty
01Jul19 07:16
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Oxford BioMedica (OXB): Eying up long-term value
27Jun19 07:00
Allergy Therapeutics plc
0.00%
Successful Litigation Settlement
27Jun19 07:00
Allergy Therapeutics plc
0.00%
Trading Statement
19Jun19 07:00
Allergy Therapeutics plc
0.00%
Board Change
11Jun19 07:00
Allergy Therapeutics plc
0.00%
Holdings in Company
21May19 08:30
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Titon Holdings Plc (TON): You need hands
21May19 07:15
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): House dust mite vaccine - clinical progress
20May19 07:00
Allergy Therapeutics plc
0.00%
Positive top line phase I results for Acarovac MPL
14May19 07:00
Allergy Therapeutics plc
0.00%
Holdings in Company
13May19 18:14
Allergy Therapeutics plc
0.00%
Holding(s) in Company
07May19 07:00
Allergy Therapeutics plc
0.00%
Research Published on Adjuvant Systems
25Apr19 07:00
Allergy Therapeutics plc
0.00%
Regulatory and Trading Update
18Mar19 11:30
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Take an objective view
18Mar19 07:00
Allergy Therapeutics plc
0.00%
Top Line Phase III results from B301 trial
06Mar19 12:10
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Strong operating performance driving market share
06Mar19 07:00
Allergy Therapeutics plc
0.00%
Interim Results
17Jan19 09:56
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Trading update: gaining market share
16Jan19 07:00
Allergy Therapeutics plc
0.00%
Trading Update & Notice of Results
29Nov18 17:59
Allergy Therapeutics plc
0.00%
Holdings in Company
27Nov18 13:12
Allergy Therapeutics plc
0.00%
Result of AGM
27Nov18 07:00
Allergy Therapeutics plc
0.00%
AGM Trading Update
12Nov18 12:00
Allergy Therapeutics plc
0.00%
Presentation at Jefferies Healthcare Conference
08Nov18 07:00
Allergy Therapeutics plc
0.00%
Directorate Change
07Nov18 18:06
Allergy Therapeutics plc
0.00%
Holdings in Company
02Nov18 07:00
Allergy Therapeutics plc
0.00%
Grant of Awards under Long Term Incentive Plan
24Oct18 13:25
Allergy Therapeutics plc
0.00%
Holdings in Company
24Oct18 07:00
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
23Oct18 17:29
Allergy Therapeutics plc
0.00%
Annual Report and Accounts
23Oct18 15:28
Allergy Therapeutics plc
0.00%
Holdings in Company
27Sep18 07:15
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): 2018 full-year results: solid growth
08Aug18 07:00
Allergy Therapeutics plc
0.00%
Notice of Results
27Jul18 17:26
Allergy Therapeutics plc
0.00%
Holding(s) in Company
26Jul18 12:02
Allergy Therapeutics plc
0.00%
Holding(s) in Company
19Jul18 10:19
Allergy Therapeutics plc
0.00%
Results of Placing and Subscription
19Jul18 07:00
Allergy Therapeutics plc
0.00%
Proposed placing & subscription to raise £10.6m
13Jul18 09:40
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Steady performance in a tough market
12Jul18 07:00
Allergy Therapeutics plc
0.00%
Trading Update
21May18 12:25
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Opening the door to registration
21May18 07:00
Allergy Therapeutics plc
0.00%
Positive top-line results from Grass Ph II study
16Mar18 15:38
Allergy Therapeutics plc
0.00%
Grant of Awards under Long Term Incentive Plan
16Mar18 12:53
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
07Mar18 07:00
Allergy Therapeutics plc
0.00%
Interim Results
28Feb18 07:00
Allergy Therapeutics plc
0.00%
Polyvac® Peanut CMO appointed
12Feb18 07:00
Allergy Therapeutics plc
0.00%
Completion of recruitment in PQ Grass Ph II trial
31Jan18 07:00
Allergy Therapeutics plc
0.00%
Trading Update
10Jan18 15:19
Allergy Therapeutics plc
0.00%
Holdings in Company
09Jan18 07:00
Allergy Therapeutics plc
0.00%
PQ Birch Phase III trial completes recruitment
07Dec17 17:08
Allergy Therapeutics plc
0.00%
Holding(s) in Company
22Nov17 11:36
Allergy Therapeutics plc
0.00%
Result of AGM
07Nov17 12:59
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
07Nov17 11:54
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
19Oct17 16:14
Allergy Therapeutics plc
0.00%
Publication of Annual Report and notice of AGM
19Oct17 07:00
Allergy Therapeutics plc
0.00%
Commencement of dosing in PQ Grass Phase II Trial
12Oct17 17:39
Allergy Therapeutics plc
0.00%
Holding(s) in Company
12Oct17 14:55
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
«
1
2
3
»
Strapline
Strapline
Question 1
Answer 1
Question 2
Answer 2
Question 3
Answer 3
Question 4
Answer 4
Question 5
Answer 5
Question 6
Answer 6
Question 7
Answer 7
Question 8
Answer 8
Top
Home
Features
Pricing
Event Hub
Reg.News
Short Interest Tracker
Explore Content
Regions
UK
Rest of EMEA
N America
APAC
LatAm
Exchanges
Aquis Apex
Australian Securities Exchange
Canadian Securities Exchange
Euronext Paris
London Stock Exchange (domestic)
SIX Swiss Exchange
Sectors
Automobile Industry
Banks
Building & Construction
Chemicals
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Utilities
Small / Large Cap
UK100
UK250
UK Smallcap
UK Other Main Markets
Other
Private/EIS
EIS Single Company
EIS/SEIS Funds
IHT Products
SEIS Single Company
VCT Funds
Providers
Free/Commissioned
ACF Equity Research
Actio Advisors
Align Research
Atrium Research
BlytheRay
BNP Paribas Exane - Sponsored Research
Brand Communications
BRR Media
Calvine Partners
Capital Access Group
Capital Markets Brokers
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Edison
Equity Development
eResearch
Fidante Partners
Five Minute Pitch TV
focusIR
Fundamental Research Corp
Galliano’s Latin Notes
goetzpartners securities Limited
H2 Radnor
Hardman & Co
Holland Advisors
Hypothesis Research
Inbound Capital
Independent Investment Research
InterAxS Global
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Magnitogorsk Iron and steel works
Mello Events
Mining Network
NuWays
Paul Scott
Peel Hunt
piworld.co.uk
Proactive
Progressive Equity Research
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Resolve Research
SEAL Advisors Ltd
ShareSoc
Shore Capital
Small Cap Consumer Research LLC
StockBox
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
Turner Pope Investments
UK Investor Group
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
High Net Worth Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
AlphaValue
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
Baptista Research
BNP Paribas Exane - Sponsored Research
Canaccord Genuity
Cavendish
Couloir Capital
Dowgate Capital
First Berlin
First Sentinel
GSBR Research
Hannam & Partners
Hybridan
Kemeny Capital
Liberum
Longspur Clean Energy
Louis Capital
Magnitogorsk Iron and steel works
Medley Global Advisors
Northland Capital Partners
QuotedData Professional
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
SP Angel
Stanford Capital Partners
Stifel FirstEnergy
Stockdale Securities
Tamesis Partners
Tennyson Securities
The Life Sciences Division
Turner Pope Investments
VSA Capital
WHIreland
Whitman Howard
Yellowstone Advisory
Zeus Capital
Institutional Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
BNP Paribas Exane
BRR Media
Calvine Partners
Canaccord Genuity
Capital Access Group
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Dowgate Capital
Edison
Equity Development
eResearch
Fidante Partners
First Berlin
First Sentinel
Five Minute Pitch TV
Fundamental Research Corp
Galliano’s Latin Notes
Goodbody
H2 Radnor
Hannam & Partners
Hardman & Co
Holland Advisors
Hybridan
Inbound Capital
Independent Investment Research
InterAxS Global
Investec Bank
Kemeny Capital
Kepler | Absolute Hedge
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Longspur Clean Energy
Magnitogorsk Iron and steel works
Mello Events
Mining Network
Northland Capital Partners
Numis
NuWays
Panmure Gordon
Peel Hunt
piworld.co.uk
Proactive
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
Small Cap Consumer Research LLC
SP Angel
Stanford Capital Partners
Stifel
StockBox
Tamesis Partners
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
UK Investor Group
Velocity Trade
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
Contact
Sign Up
Sign In
Share: